Status:
COMPLETED
Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Chiron Corporation
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients with a CD4 cell count over 200/mm3, but its activity in patients with treatment failure and low CD4 cell counts is unk...
Detailed Description
IL-2 is produced naturally in the body and helps CD4 cells multiply. In earlier studies in HIV-infection, most of the patients with a controlled viral load and a high level of CD4 count (over 200/mm3)...
Eligibility Criteria
Inclusion
- Adult patients with proven HIV-1-infection
- Prior or current exposition to at least 1 molecule from each of the 3 antiretroviral classes (NRTI, NNRTI and PI)
- In a situation of therapeutic failure on an ongoing regimen
Exclusion
- Patients included in the Macrolin® expanded French access program
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00113282
Start Date
June 1 2004
End Date
February 1 2008
Last Update
December 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Necker service des Maladies Infectieuses
Paris, France, 75015